• Policy
• ‘Skilarence’ may be reimbursed if it accepts PBAC's price
• by Lee, Hye-Kyung Oct 13, 2021 05:46am

• Policy
• Drug prices are the key to easing the PAH benefit standard
• by Choi-sun Oct 13, 2021 05:46am

• Policy
• Hanmi's HM15912 is approved for phase 2 in Korea
• by Lee, Tak-Sun Oct 12, 2021 05:50am

• Policy
• Gov “It was the experts’ decision to not list Kymriah”
• by Kim, Jung-Ju Oct 12, 2021 05:49am

• Policy
• The MOHW expressed reluctance to Keytruda's primary benefit
• by Lee, Jeong-Hwan Oct 12, 2021 05:49am

• Policy
• Pfizer vaccines from Romania not transported in official box
• by Lee, Jeong-Hwan Oct 8, 2021 05:56am

• Policy
• Expanding the submission of opinions reflecting permission
• by Lee, Tak-Sun Oct 7, 2021 05:54am

• Policy
• ’With Covid’ scheme unclear with over 5,000 cases expected
• by Lee, Jeong-Hwan Oct 7, 2021 05:53am

• Policy
• Nexviazyme has been applied for domestic permission
• by Lee, Tak-Sun Oct 7, 2021 05:53am

• Policy
• Introduction of pre-registration is difficult
• by Kim, Jung-Ju Oct 7, 2021 05:53am